BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31801803)

  • 1. DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.
    Kato S; Takahashi T; Miyata N; Roman RJ
    J Pharmacol Exp Ther; 2020 Feb; 372(2):166-174. PubMed ID: 31801803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-inducible factor-prolyl hydroxylase inhibitor Roxadustat (FG-4592) reduces renal fibrosis in Dahl salt-sensitive rats.
    Naito Y; Yasumura S; Okuno K; Asakura M; Tsujino T; Masuyama T; Ishihara M
    J Hypertens; 2024 Mar; 42(3):497-505. PubMed ID: 38014420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia.
    Packer M
    Am J Nephrol; 2024; 55(2):255-259. PubMed ID: 37231827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of collagen IV alpha-2 subunit by prolyl hydroxylase domain inhibition via hypoxia-inducible factor-1 in chronic kidney disease.
    Sanaei-Ardekani M; Kamal S; Handy W; Alam S; Salaheldin A; Moore A; Movafagh S
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00872. PubMed ID: 34617686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
    Uchida L; Tanaka T; Saito H; Sugahara M; Wakashima T; Fukui K; Nangaku M
    Am J Physiol Renal Physiol; 2020 Feb; 318(2):F388-F401. PubMed ID: 31841388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
    Zuk A; Si Z; Loi S; Bommegowda S; Hoivik D; Danthi S; Molnar G; Csizmadia V; Rabinowitz M
    J Pharmacol Exp Ther; 2022 Oct; 383(1):11-24. PubMed ID: 35926869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.
    Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
    Clin Exp Pharmacol Physiol; 2016 Mar; 43(3):343-54. PubMed ID: 26889660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of prolyl-hydroxylase inhibition and chronic intermittent hypoxia on synaptic transmission and plasticity in the rat CA1 and dentate gyrus.
    Wall AM; Corcoran AE; O'Halloran KD; O'Connor JJ
    Neurobiol Dis; 2014 Feb; 62():8-17. PubMed ID: 24055213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daprodustat: First Approval.
    Dhillon S
    Drugs; 2020 Sep; 80(14):1491-1497. PubMed ID: 32880805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prolyl hydroxylase inhibitor dimethyloxalylglycine enhances dentin sialophoshoprotein expression through VEGF-induced Runx2 stabilization.
    Rahman SU; Lee MS; Baek JH; Ryoo HM; Woo KM
    PLoS One; 2014; 9(11):e112078. PubMed ID: 25369078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver.
    Kato S; Ochiai N; Takano H; Io F; Takayama N; Koretsune H; Kunioka EI; Uchida S; Yamamoto K
    J Pharmacol Exp Ther; 2019 Dec; 371(3):675-683. PubMed ID: 31585986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia.
    Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
    Biochimie; 2016 Jun; 125():150-62. PubMed ID: 27039028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotally nephrectomized rats.
    Zhang A; Nakano D; Morisawa N; Kitada K; Kittikulsuth W; Rahman A; Morikawa T; Konishi Y; Nishiyama A
    J Pharmacol Sci; 2021 Jun; 146(2):98-104. PubMed ID: 33941326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney.
    Song YR; You SJ; Lee YM; Chin HJ; Chae DW; Oh YK; Joo KW; Han JS; Na KY
    Nephrol Dial Transplant; 2010 Jan; 25(1):77-85. PubMed ID: 19737871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation.
    Palaniyandi S; Kumari R; Venniyil Radhakrishnan S; Strattan E; Hakim N; Munker R; Kesler MV; Hildebrandt GC
    Transplantation; 2020 Dec; 104(12):2507-2515. PubMed ID: 32639407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Salt Diet Aggravates Endothelial-to-Mesenchymal Transition in Glomerular Fibrosis in Dahl Salt-Sensitive Rats.
    Chen HL; Peng K; Zeng DM; Yan J; Huang YQ; Jiang PY; Du YF; Ling X; Wu J
    Am J Hypertens; 2023 Nov; 36(12):660-666. PubMed ID: 37179466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.
    Williams JM; Zhang J; North P; Lacy S; Yakes M; Dahly-Vernon A; Roman RJ
    Am J Physiol Renal Physiol; 2011 Apr; 300(4):F983-98. PubMed ID: 21228113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of prolyl hydroxylases alters cell metabolism and reverses pre-existing diastolic dysfunction in mice.
    He X; Zeng H; Roman RJ; Chen JX
    Int J Cardiol; 2018 Dec; 272():281-287. PubMed ID: 30177233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of HIF prolyl-hydroxylase 2 gene in the renal medulla attenuates salt-sensitive hypertension in Dahl S rats.
    Zhu Q; Hu J; Han WQ; Zhang F; Li PL; Wang Z; Li N
    Am J Hypertens; 2014 Jan; 27(1):107-13. PubMed ID: 24190904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress.
    Joharapurkar AA; Patel VJ; Kshirsagar SG; Patel MS; Savsani HH; Jain MR
    Drug Dev Res; 2021 Sep; 82(6):852-860. PubMed ID: 33480036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.